二甲双胍与2型糖尿病患者卵巢癌风险及预后关系的meta分析OACSTPCD

Objective:To assess the risk of ovarian neoplasms and oncologic outcomes among patients with type 2 diabetes who underwent treatment with metformin.Methods:We conducted a systematic literature search on PubMed,Embase,Web of Science,SinoMed,VIP,Wanfang,and CNKI.The subject terms employed for retrieval encompassed type 2 diabetes,metformin,ovarian cancer risk,and prognosis.The retrieval timeframe spanned from the incep-tion of the database until February 1,2023.Meta-analysis was performed using Review Manager(RevMan)software version 5.3.Results:A comprehensive analysis was conducted,incorpora-ting a total of 15 studies,all of which were determined to possess a high level of quality based on a mean Newcastle-Ottawa Scale(NOS)score of 7.5.The meta-analysis revealed that the u-tilization of metformin did not exhibit a significant reduction in the incidence of ovarian neo-plasms in patients with type 2 diabetes(HR=0.87,95%CI 0.70～1.10,P=0.24).However,it did demonstrate a notable extension in overall survival(OS)(HR=0.51,95%CI 0.35～0.75,P=0.0006)and progression-free survival(PFS)(HR=0.37,95%CI 0.27～0.51,P<0.00001).Conclusion:The results of the study revealed that although metformin did not exhib-it a decrease in the occurrence of ovarian cancer,it may enhance both overall survival and pro-gression-free survival in individuals diagnosed with type 2 diabetes and ovarian cancer.